Replies to post #13 on Sol Gel Technologies Ltd (SLGL)

[midastouch017]

BLRX soaked quite a lot of $$$
from my bank account. I left some
shares just for academic interest.

KTOV was one on my largest failures,
although i am in the deep red i still
keep it, for offsetting some gains in
others some time.

PARS was my largest loss by far, a
few years ago

TEVA was my largest gain ever.

BVXV has imo the largest potential if
of course they achieve FDA approval.
That said, there have been great Israeli
bio company success stories, and some
loud shattering collapses as well.

Take into consideration that Israel is #1
in foreign companies listed in the US.

Good Luck

[midastouch017]

Re: BVXV

good news is trial is over and results
will by end of the year.

Another earlier indication might come soon:

JERUSALEM, Feb. 5, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have been published. The trial was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The primary objectives of the trial were to assess safety and T-cell responses to M-001. The data, which are consistent with results of previous clinical trials of M-001, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.

https://www.prnewswire.com/il/news-releases/preliminary-data-from-nihniaid-sponsored-phase-2-clinical-trial-of-biondvaxs-m-001-universal-influenza-vaccine-candidate-validates-results-of-previous-clinical-trials-300999644.html

Anyway, $6 entry point would be very attractive!

:-)

[midastouch017]

This one has potential - good news is trial is over and results will by end of the year.
If it drops to $6 range I might consider buying

Have you checked BVXV sp lately?

:-)

[midastouch017]

One other Israeli stock worth looking into
is BCLI.
Latest PR:

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS
PR Newswire PR Newswire•July 2, 2020
Topline data expected in 4Q 2020

https://finance.yahoo.com/news/brainstorm-announces-completion-dosing-nurown-104900360.html

BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimer’s Disease; Raising Valuation to $25/Share…
Zacks Small Cap Research Zacks Small Cap Research•July 9, 2020

https://finance.yahoo.com/news/bcli-kol-event-gives-overview-131000758.html

I think that the treshhold to obtain FDA approval is quite
low considering the gravity of the ALS disease.